Identification

Name
Bufuralol
Accession Number
DB06726
Type
Small Molecule
Groups
Experimental, Investigational
Description

Bufuralol is a new, non-selective -adrenoceptor blocking agent.

Structure
Thumb
Synonyms
  • Bufuralolum
Product Ingredients
IngredientUNIICASInChI Key
Bufuralol hydrochlorideG66IY7Q7S460398-91-6KJBONRGCLLBWCJ-UHFFFAOYSA-N
Categories
UNII
891H89GFT4
CAS number
54340-62-4
Weight
Average: 261.3593
Monoisotopic: 261.172878985
Chemical Formula
C16H23NO2
InChI Key
SSEBTPPFLLCUMN-UHFFFAOYSA-N
InChI
InChI=1S/C16H23NO2/c1-5-11-7-6-8-12-9-14(19-15(11)12)13(18)10-17-16(2,3)4/h6-9,13,17-18H,5,10H2,1-4H3
IUPAC Name
2-(tert-butylamino)-1-(7-ethyl-1-benzofuran-2-yl)ethan-1-ol
SMILES
CCC1=CC=CC2=C1OC(=C2)C(O)CNC(C)(C)C

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UBeta adrenergic receptor
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Bufuralol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Experimental, Illicit
AbirateroneThe serum concentration of Bufuralol can be increased when it is combined with Abiraterone.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Bufuralol.Approved
AcemetacinAcemetacin may decrease the antihypertensive activities of Bufuralol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Bufuralol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Bufuralol.Approved
AcetohexamideBufuralol may increase the hypoglycemic activities of Acetohexamide.Withdrawn
AcetylcholineThe risk or severity of adverse effects can be increased when Bufuralol is combined with Acetylcholine.Approved
AcetyldigitoxinBufuralol may increase the bradycardic activities of Acetyldigitoxin.Approved
AcetyldigoxinBufuralol may increase the bradycardic activities of Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Bufuralol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Bufuralol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Experimental, Investigational
AlaproclateThe serum concentration of Bufuralol can be increased when it is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the antihypertensive activities of Bufuralol.Approved, Withdrawn
AlfentanilAlfentanil may increase the bradycardic activities of Bufuralol.Approved, Illicit
AlfuzosinBufuralol may increase the orthostatic hypotensive activities of Alfuzosin.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Bufuralol.Approved, Vet Approved
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Bufuralol.Experimental
AmbenoniumAmbenonium may increase the bradycardic activities of Bufuralol.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Bufuralol.Approved, Investigational
AmobarbitalThe serum concentration of Bufuralol can be decreased when it is combined with Amobarbital.Approved, Illicit
AmodiaquineThe metabolism of Bufuralol can be decreased when combined with Amodiaquine.Approved
AndrographolideAndrographolide may decrease the antihypertensive activities of Bufuralol.Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Bufuralol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Bufuralol.Approved
ApocyninApocynin may decrease the antihypertensive activities of Bufuralol.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Approved, Investigational
ApremilastApremilast may decrease the antihypertensive activities of Bufuralol.Approved, Investigational
ArecolineThe risk or severity of adverse effects can be increased when Bufuralol is combined with Arecoline.Experimental
ArtemetherThe metabolism of Bufuralol can be decreased when combined with Artemether.Approved
AtomoxetineThe metabolism of Bufuralol can be decreased when combined with Atomoxetine.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Bufuralol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Bufuralol.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Bufuralol.Approved, Investigational
BarbexacloneThe serum concentration of Bufuralol can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe serum concentration of Bufuralol can be decreased when it is combined with Barbital.Illicit
BendazacBendazac may decrease the antihypertensive activities of Bufuralol.Experimental
BenorilateBenorilate may decrease the antihypertensive activities of Bufuralol.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Bufuralol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Approved, Illicit
BetaxololThe metabolism of Bufuralol can be decreased when combined with Betaxolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Bufuralol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Approved
BevoniumBevonium may decrease the antihypertensive activities of Bufuralol.Experimental
BL-1020BL-1020 may increase the hypotensive activities of Bufuralol.Investigational
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Bufuralol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Bufuralol.Investigational
BucindololBufuralol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Bufuralol.Experimental
BumadizoneBumadizone may decrease the antihypertensive activities of Bufuralol.Experimental
BunazosinBufuralol may increase the orthostatic hypotensive activities of Bunazosin.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Bufuralol.Approved, Investigational
BupropionThe metabolism of Bufuralol can be decreased when combined with Bupropion.Approved
CabergolineBufuralol may increase the vasoconstricting activities of Cabergoline.Approved
CarbacholThe risk or severity of adverse effects can be increased when Bufuralol is combined with Carbachol.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Bufuralol.Experimental
CarbutamideBufuralol may increase the hypoglycemic activities of Carbutamide.Experimental
CarprofenCarprofen may decrease the antihypertensive activities of Bufuralol.Approved, Vet Approved, Withdrawn
CarvedilolBufuralol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Bufuralol.Experimental
CelecoxibThe metabolism of Bufuralol can be decreased when combined with Celecoxib.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when Bufuralol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Bufuralol can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorproethazineChlorproethazine may increase the hypotensive activities of Bufuralol.Experimental
ChlorpromazineThe metabolism of Bufuralol can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideBufuralol may increase the hypoglycemic activities of Chlorpropamide.Approved
CholecalciferolThe metabolism of Bufuralol can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Bufuralol.Approved
CimetidineThe metabolism of Bufuralol can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Bufuralol can be decreased when combined with Cinacalcet.Approved
CitalopramThe metabolism of Bufuralol can be decreased when combined with Citalopram.Approved
ClemastineThe metabolism of Bufuralol can be decreased when combined with Clemastine.Approved
ClobazamThe metabolism of Bufuralol can be decreased when combined with Clobazam.Approved, Illicit
ClomipramineThe metabolism of Bufuralol can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Bufuralol.Approved
ClotrimazoleThe metabolism of Bufuralol can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Bufuralol can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Bufuralol can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Bufuralol can be decreased when combined with Cocaine.Approved, Illicit
CoumaphosCoumaphos may increase the bradycardic activities of Bufuralol.Vet Approved
CurcuminCurcumin may decrease the antihypertensive activities of Bufuralol.Investigational
CymarinBufuralol may increase the bradycardic activities of Cymarin.Experimental
D-LimoneneD-Limonene may decrease the antihypertensive activities of Bufuralol.Investigational
DapoxetineThe serum concentration of Bufuralol can be increased when it is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Bufuralol can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Bufuralol can be increased when it is combined with Darunavir.Approved
DecamethoniumDecamethonium may increase the bradycardic activities of Bufuralol.Approved
DelavirdineThe metabolism of Bufuralol can be decreased when combined with Delavirdine.Approved
DemecariumDemecarium may increase the bradycardic activities of Bufuralol.Approved
DesipramineThe metabolism of Bufuralol can be decreased when combined with Desipramine.Approved
DeslanosideBufuralol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Bufuralol can be increased when it is combined with Desvenlafaxine.Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Approved, Vet Approved
DichlorvosDichlorvos may increase the bradycardic activities of Bufuralol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Bufuralol.Approved, Vet Approved
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Bufuralol.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Bufuralol.Approved
DigitoxinBufuralol may increase the bradycardic activities of Digitoxin.Approved
DigoxinBufuralol may increase the bradycardic activities of Digoxin.Approved
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Approved
DiltiazemDiltiazem may increase the hypotensive activities of Bufuralol.Approved
DiphenhydramineThe metabolism of Bufuralol can be decreased when combined with Diphenhydramine.Approved
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Bufuralol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Bufuralol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Bufuralol.Approved
DistigmineDistigmine may increase the bradycardic activities of Bufuralol.Experimental
DonepezilDonepezil may increase the bradycardic activities of Bufuralol.Approved
DosulepinThe metabolism of Bufuralol can be decreased when combined with Dosulepin.Approved
DoxazosinBufuralol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DronedaroneDronedarone may increase the bradycardic activities of Bufuralol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Bufuralol.Approved
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Bufuralol.Approved, Investigational
DuloxetineThe metabolism of Bufuralol can be decreased when combined with Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Bufuralol.Investigational
E-6201E-6201 may decrease the antihypertensive activities of Bufuralol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Bufuralol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Bufuralol.Approved
EliglustatThe metabolism of Bufuralol can be decreased when combined with Eliglustat.Approved
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Bufuralol.Approved, Nutraceutical, Withdrawn
EpibatidineThe risk or severity of adverse effects can be increased when Bufuralol is combined with Epibatidine.Experimental
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Bufuralol.Approved
Ergoloid mesylateBufuralol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineBufuralol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Bufuralol.Approved, Investigational
EthenzamideEthenzamide may decrease the antihypertensive activities of Bufuralol.Experimental
EtodolacEtodolac may decrease the antihypertensive activities of Bufuralol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Bufuralol.Approved
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Bufuralol.Approved
EtoperidoneThe serum concentration of Bufuralol can be increased when it is combined with Etoperidone.Approved
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Bufuralol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Bufuralol.Approved
exisulindexisulind may decrease the antihypertensive activities of Bufuralol.Investigational
FelbinacFelbinac may decrease the antihypertensive activities of Bufuralol.Experimental
FenbufenFenbufen may decrease the antihypertensive activities of Bufuralol.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Bufuralol.Approved
FentanylFentanyl may increase the bradycardic activities of Bufuralol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Bufuralol.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Bufuralol.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Bufuralol.Experimental
Ferulic acidFerulic acid may decrease the antihypertensive activities of Bufuralol.Experimental
FingolimodBufuralol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Bufuralol.Approved, Withdrawn
FlunixinFlunixin may decrease the antihypertensive activities of Bufuralol.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Bufuralol.Experimental
FluoxetineThe metabolism of Bufuralol can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Bufuralol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Bufuralol.Approved, Investigational
FluvoxamineThe metabolism of Bufuralol can be decreased when combined with Fluvoxamine.Approved, Investigational
GalantamineGalantamine may increase the bradycardic activities of Bufuralol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Bufuralol.Approved
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Bufuralol.Approved, Nutraceutical
GitoformateBufuralol may increase the bradycardic activities of Gitoformate.Experimental
GlibornurideBufuralol may increase the hypoglycemic activities of Glibornuride.Withdrawn
GliclazideBufuralol may increase the hypoglycemic activities of Gliclazide.Approved
GlipizideBufuralol may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneBufuralol may increase the hypoglycemic activities of Gliquidone.Approved
GlisoxepideBufuralol may increase the hypoglycemic activities of Glisoxepide.Approved
GlyburideBufuralol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Bufuralol is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Bufuralol.Experimental
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Bufuralol.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Approved, Investigational
HaloperidolThe metabolism of Bufuralol can be decreased when combined with Haloperidol.Approved
HexobarbitalThe serum concentration of Bufuralol can be decreased when it is combined with Hexobarbital.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Bufuralol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Bufuralol.Investigational
HydroxychloroquineThe metabolism of Bufuralol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Bufuralol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Bufuralol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Bufuralol.Approved
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Bufuralol.Experimental
ImipramineThe metabolism of Bufuralol can be decreased when combined with Imipramine.Approved
IndalpineThe serum concentration of Bufuralol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Bufuralol can be decreased when combined with Indinavir.Approved
IndobufenIndobufen may decrease the antihypertensive activities of Bufuralol.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Bufuralol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Bufuralol.Withdrawn
IndoraminBufuralol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin PorkBufuralol may increase the hypoglycemic activities of Insulin Pork.Approved
IpidacrineIpidacrine may increase the bradycardic activities of Bufuralol.Experimental
IsoflurophateIsoflurophate may increase the bradycardic activities of Bufuralol.Approved, Withdrawn
IsoniazidThe metabolism of Bufuralol can be decreased when combined with Isoniazid.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Bufuralol.Withdrawn
KebuzoneKebuzone may decrease the antihypertensive activities of Bufuralol.Experimental
KetoconazoleThe metabolism of Bufuralol can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Bufuralol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Bufuralol.Approved
LabetalolBufuralol may increase the orthostatic hypotensive activities of Labetalol.Approved
Lanatoside CBufuralol may increase the bradycardic activities of Lanatoside C.Experimental
LeflunomideLeflunomide may decrease the antihypertensive activities of Bufuralol.Approved, Investigational
LevomilnacipranThe serum concentration of Bufuralol can be increased when it is combined with Levomilnacipran.Approved
LevonordefrinLevonordefrin may increase the atrioventricular blocking (AV block) activities of Bufuralol.Approved
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Bufuralol.Approved, Vet Approved
LisofyllineLisofylline may decrease the antihypertensive activities of Bufuralol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Bufuralol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Approved, Investigational
LonazolacLonazolac may decrease the antihypertensive activities of Bufuralol.Experimental
LopinavirThe metabolism of Bufuralol can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Bufuralol can be decreased when combined with Lorcaserin.Approved
LornoxicamLornoxicam may decrease the antihypertensive activities of Bufuralol.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Bufuralol.Approved
LumefantrineThe metabolism of Bufuralol can be decreased when combined with Lumefantrine.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Bufuralol.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Bufuralol.Approved
MalathionMalathion may increase the bradycardic activities of Bufuralol.Approved, Investigational
ManidipineThe metabolism of Bufuralol can be decreased when combined with Manidipine.Approved
MasoprocolMasoprocol may decrease the antihypertensive activities of Bufuralol.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Bufuralol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Bufuralol.Approved
MefloquineMefloquine may increase the bradycardic activities of Bufuralol.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Bufuralol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Bufuralol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Bufuralol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Bufuralol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Bufuralol.Approved
MetahexamideBufuralol may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Bufuralol.Withdrawn
MethacholineThe risk or severity of adverse effects can be increased when Bufuralol is combined with Methacholine.Approved
MethadoneThe metabolism of Bufuralol can be decreased when combined with Methadone.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Bufuralol.Investigational
MethohexitalThe serum concentration of Bufuralol can be decreased when it is combined with Methohexital.Approved
MethotrimeprazineThe metabolism of Bufuralol can be decreased when combined with Methotrimeprazine.Approved
Methyl salicylateMethyl salicylate may increase the bradycardic activities of Bufuralol.Approved, Vet Approved
Methylene blueMethylene blue may increase the hypotensive activities of Bufuralol.Investigational
MethylergometrineBufuralol may increase the vasoconstricting activities of Methylergometrine.Approved
MethylphenobarbitalThe serum concentration of Bufuralol can be decreased when it is combined with Methylphenobarbital.Approved
MetildigoxinBufuralol may increase the bradycardic activities of Metildigoxin.Experimental
MetoclopramideMetoclopramide may increase the bradycardic activities of Bufuralol.Approved, Investigational
MetoprololThe metabolism of Bufuralol can be decreased when combined with Metoprolol.Approved, Investigational
MidodrineBufuralol may increase the bradycardic activities of Midodrine.Approved
MidostaurinThe metabolism of Bufuralol can be decreased when combined with Midostaurin.Approved
MilnacipranThe serum concentration of Bufuralol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Bufuralol.Approved
MirabegronThe metabolism of Bufuralol can be decreased when combined with Mirabegron.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Bufuralol.Investigational
MofebutazoneMofebutazone may decrease the antihypertensive activities of Bufuralol.Experimental
MoricizineMoricizine may increase the hypotensive activities of Bufuralol.Approved, Withdrawn
MoxonidineMoxonidine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Approved
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Bufuralol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Bufuralol.Approved
NabumetoneNabumetone may decrease the antihypertensive activities of Bufuralol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Bufuralol.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Bufuralol.Approved
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Bufuralol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Bufuralol.Approved, Vet Approved
NefazodoneThe serum concentration of Bufuralol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Bufuralol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Bufuralol.Approved
NevirapineThe metabolism of Bufuralol can be decreased when combined with Nevirapine.Approved
NicardipineThe metabolism of Bufuralol can be decreased when combined with Nicardipine.Approved
NicotineThe risk or severity of adverse effects can be increased when Bufuralol is combined with Nicotine.Approved
NifedipineNifedipine may increase the hypotensive activities of Bufuralol.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Bufuralol.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Bufuralol.Approved
NilotinibThe metabolism of Bufuralol can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideNimesulide may decrease the antihypertensive activities of Bufuralol.Approved, Withdrawn
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Bufuralol.Investigational
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Approved
OleandrinBufuralol may increase the bradycardic activities of Oleandrin.Experimental
OlopatadineOlopatadine may decrease the antihypertensive activities of Bufuralol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Bufuralol.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Bufuralol.Vet Approved
OuabainBufuralol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Bufuralol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Bufuralol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Bufuralol.Withdrawn
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Bufuralol.Approved
PanobinostatThe serum concentration of Bufuralol can be increased when it is combined with Panobinostat.Approved, Investigational
ParaoxonParaoxon may increase the bradycardic activities of Bufuralol.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Bufuralol.Approved
ParoxetineThe metabolism of Bufuralol can be decreased when combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the antihypertensive activities of Bufuralol.Investigational
Peginterferon alfa-2bThe serum concentration of Bufuralol can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentobarbitalThe serum concentration of Bufuralol can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerazinePerazine may increase the hypotensive activities of Bufuralol.Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Bufuralol.Approved, Vet Approved, Withdrawn
PerphenazinePerphenazine may increase the hypotensive activities of Bufuralol.Approved
PeruvosideBufuralol may increase the bradycardic activities of Peruvoside.Experimental
PhenobarbitalThe serum concentration of Bufuralol can be decreased when it is combined with Phenobarbital.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Bufuralol.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Approved, Vet Approved, Withdrawn
PhysostigminePhysostigmine may increase the bradycardic activities of Bufuralol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Bufuralol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Bufuralol.Approved, Investigational
PirfenidonePirfenidone may decrease the antihypertensive activities of Bufuralol.Investigational
PiroxicamPiroxicam may decrease the antihypertensive activities of Bufuralol.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Bufuralol.Experimental
PranoprofenPranoprofen may decrease the antihypertensive activities of Bufuralol.Experimental
PrazosinBufuralol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrimaquineThe metabolism of Bufuralol can be decreased when combined with Primaquine.Approved
PrimidoneThe serum concentration of Bufuralol can be decreased when it is combined with Primidone.Approved, Vet Approved
ProchlorperazineProchlorperazine may increase the hypotensive activities of Bufuralol.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Bufuralol.Experimental
PromazineThe metabolism of Bufuralol can be decreased when combined with Promazine.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Bufuralol.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Bufuralol.Approved
PropafenoneThe serum concentration of Bufuralol can be increased when it is combined with Propafenone.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Bufuralol.Vet Approved
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Bufuralol.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Bufuralol.Experimental
ProscillaridinBufuralol may increase the bradycardic activities of Proscillaridin.Experimental
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Bufuralol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Bufuralol.Approved
QuinidineThe metabolism of Bufuralol can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Bufuralol can be decreased when combined with Quinine.Approved
RanolazineThe metabolism of Bufuralol can be decreased when combined with Ranolazine.Approved, Investigational
RegorafenibRegorafenib may increase the bradycardic activities of Bufuralol.Approved
RemifentanilRemifentanil may increase the bradycardic activities of Bufuralol.Approved
ReserpineReserpine may increase the hypotensive activities of Bufuralol.Approved
ResveratrolResveratrol may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
RifampicinThe serum concentration of Bufuralol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Bufuralol can be decreased when it is combined with Rifapentine.Approved
RisperidoneRisperidone may increase the atrioventricular blocking (AV block) activities of Bufuralol.Approved, Investigational
RitonavirThe metabolism of Bufuralol can be decreased when combined with Ritonavir.Approved, Investigational
RivastigmineRivastigmine may increase the bradycardic activities of Bufuralol.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Bufuralol.Investigational, Withdrawn
RolapitantThe metabolism of Bufuralol can be decreased when combined with Rolapitant.Approved
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Bufuralol.Approved, Investigational
SalicylamideSalicylamide may decrease the antihypertensive activities of Bufuralol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Bufuralol.Approved, Vet Approved
SalsalateSalsalate may decrease the antihypertensive activities of Bufuralol.Approved
SecobarbitalThe serum concentration of Bufuralol can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SemapimodSemapimod may decrease the antihypertensive activities of Bufuralol.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Bufuralol.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Bufuralol.Investigational
SertralineThe metabolism of Bufuralol can be decreased when combined with Sertraline.Approved
SilodosinBufuralol may increase the orthostatic hypotensive activities of Silodosin.Approved
SRT501SRT501 may decrease the antihypertensive activities of Bufuralol.Investigational
StiripentolThe metabolism of Bufuralol can be decreased when combined with Stiripentol.Approved
SufentanilSufentanil may increase the bradycardic activities of Bufuralol.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Bufuralol.Approved
SulindacSulindac may decrease the antihypertensive activities of Bufuralol.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Bufuralol.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Bufuralol.Experimental
TacrineTacrine may increase the bradycardic activities of Bufuralol.Withdrawn
TamsulosinBufuralol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Bufuralol.Investigational
TenidapTenidap may decrease the antihypertensive activities of Bufuralol.Experimental
TenoxicamTenoxicam may decrease the antihypertensive activities of Bufuralol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Bufuralol.Vet Approved
TerazosinBufuralol may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbinafineThe metabolism of Bufuralol can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Bufuralol.Approved
ThiamylalThe serum concentration of Bufuralol can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Bufuralol.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Bufuralol.Withdrawn
ThiopentalThe serum concentration of Bufuralol can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThioridazineThe metabolism of Bufuralol can be decreased when combined with Thioridazine.Withdrawn
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Bufuralol.Approved
TiclopidineThe metabolism of Bufuralol can be decreased when combined with Ticlopidine.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Bufuralol.Investigational
TipranavirThe metabolism of Bufuralol can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Approved
TolazamideBufuralol may increase the hypoglycemic activities of Tolazamide.Approved
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Bufuralol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Bufuralol.Approved
TranilastTranilast may decrease the antihypertensive activities of Bufuralol.Approved, Investigational
TranylcypromineThe metabolism of Bufuralol can be decreased when combined with Tranylcypromine.Approved
TribenosideTribenoside may decrease the antihypertensive activities of Bufuralol.Experimental
TrichlorfonTrichlorfon may increase the bradycardic activities of Bufuralol.Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Bufuralol.Approved
TriflupromazineTriflupromazine may increase the hypotensive activities of Bufuralol.Approved, Vet Approved
TrimazosinBufuralol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TriptolideTriptolide may decrease the antihypertensive activities of Bufuralol.Investigational
TubocurarineTubocurarine may increase the bradycardic activities of Bufuralol.Approved
UrapidilBufuralol may increase the orthostatic hypotensive activities of Urapidil.Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Bufuralol.Investigational, Withdrawn
VareniclineThe risk or severity of adverse effects can be increased when Bufuralol is combined with Varenicline.Approved, Investigational
VenlafaxineThe metabolism of Bufuralol can be decreased when combined with Venlafaxine.Approved
VerapamilVerapamil may increase the hypotensive activities of Bufuralol.Approved
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Bufuralol.Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Bufuralol.Approved
ZileutonZileuton may decrease the antihypertensive activities of Bufuralol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Bufuralol can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Bufuralol can be decreased when combined with Ziprasidone.Approved
ZomepiracZomepirac may decrease the antihypertensive activities of Bufuralol.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C13769
PubChem Compound
71733
PubChem Substance
99443272
ChemSpider
64777
BindingDB
21362
ChEBI
34593
ChEMBL
CHEMBL296035
PharmGKB
PA166110256

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP3.50HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0356 mg/mLALOGPS
logP3.24ALOGPS
logP2.99ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)13.06ChemAxon
pKa (Strongest Basic)9.24ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area45.4 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity77.43 m3·mol-1ChemAxon
Polarizability30.88 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.6584
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.6455
P-glycoprotein inhibitor INon-inhibitor0.5653
P-glycoprotein inhibitor IINon-inhibitor0.879
Renal organic cation transporterNon-inhibitor0.9148
CYP450 2C9 substrateNon-substrate0.7906
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.563
CYP450 1A2 substrateNon-inhibitor0.6892
CYP450 2C9 inhibitorNon-inhibitor0.847
CYP450 2D6 inhibitorNon-inhibitor0.6556
CYP450 2C19 inhibitorNon-inhibitor0.7983
CYP450 3A4 inhibitorNon-inhibitor0.896
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6981
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.8102
BiodegradationNot ready biodegradable0.9828
Rat acute toxicity2.5050 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9709
hERG inhibition (predictor II)Non-inhibitor0.7625
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzofurans. These are organic compounds containing a benzene ring fused to a furan. Furan is a five-membered aromatic ring with four carbon atoms and one oxygen atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzofurans
Sub Class
Not Available
Direct Parent
Benzofurans
Alternative Parents
Aralkylamines / Benzenoids / Heteroaromatic compounds / Furans / Secondary alcohols / 1,2-aminoalcohols / Oxacyclic compounds / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
show 1 more
Substituents
Benzofuran / Aralkylamine / Benzenoid / Furan / Heteroaromatic compound / 1,2-aminoalcohol / Secondary alcohol / Secondary aliphatic amine / Secondary amine / Oxacycle
show 10 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
benzofurans (CHEBI:34593)

Targets

Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...

Components:
References
  1. Zimmerman TJ, Boger WP 3rd: The beta-adrenergic blocking agents and the treatment of glaucoma. Surv Ophthalmol. 1979 May-Jun;23(6):347-62. [PubMed:37605]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Drug created on August 18, 2010 13:54 / Updated on October 02, 2017 05:46